Navigation Links
Valtrex Prevents the Need for C-Section among Women Infected With Genital Herpes

Researchers from the University of Texas, Southwestern Medical Center have found a new anti viral drug which prevents the necessity of a caesarean section //in pregnant woman who have a history of genital herpes.

The UT Southwestern study is the first large-scale confirmation that the drug valacyclovir hydrochloride (Valtrex) is effective in the last month of pregnancy, the researchers said.

The study appears in this month's issue of the journal Obstetrics and Gynecology. ‘I think this will help immensely in giving doctors stronger evidence in using this treatment,’ said Dr. Jeanne Sheffield, assistant professor of obstetrics and gynecology at UT Southwestern and lead author of the study. ‘Besides reducing the number of herpes outbreaks at birth, we also dropped the numbers of women without symptoms who were shedding the virus into the birth canal.’

Herpes, one of the most common sexually transmitted viral infections, causes periods of genital sores, followed by months or years of dormancy. It can't be cured, although the number and severity of outbreaks can be reduced through medication. Many women of reproductive age are unaware that they have the virus. In rare cases, infants can catch herpes simplex virus from the birth canal or genital region of the mother during birth, even when the mother isn't showing symptoms. Current medical protocol is to offer C-sections to all women with active genital herpes lesions at the time of delivery.

Nonetheless, 70 percent of neonatal herpes cases occur in infants of women who asymptomatically shed the virus near delivery, according to the researchers. ‘The whole goal of this study was to reduce active genital herpes lesions at delivery that require a Caesarean delivery to prevent neonatal herpes,’ Dr. Sheffield said. The UT Southwestern study, which involved 338 pregnant women with a history of genital herpes, was a randomized, double-blind trial, with neither the doctors nor the women knowing who was getting the medication. Twenty-eight women had C-sections because of active herpes lesions.

Seven of the 170 women in the valacyclovir group, or 4 percent, had the operation, while 21 of the 168 women in the placebo group, or 13 percent, had C-sections. The 69 percent reduction in the rate of clinical herpes simplex virus at the time of delivery was statistically significant, the researchers said. None of the babies in either group were born with herpes. There also were no differences in complications between the valacyclovir and placebo groups. ‘This work is a good example of a well-designed study that is of sufficient size to help clinicians and patients have confidence in the efficacy and safety of anti-viral suppression in late pregnancy,’ said Dr. George Wendel, professor of obstetrics and gynecology and senior author of the study.

Source: Eurealert
'"/>




Related medicine news :

1. Tea Prevents Skin Cancer
2. Use Of Sunscreen In Childhood And Prevents Future Skin Cancer
3. Research Shows Carbon Monoxide Prevents Inflammations
4. Polluted Water Prevents Men From Getting Married
5. Rush Study Shows That Interactions with Friends and Family Prevents Damaging Effects of Alzheimers disease
6. Fitness Prevents Alzheimers
7. Vegetarian Diet Prevents the Development of Atherosclerosis
8. Exercise in Space Prevents Kidney Stone Formation in Astronauts
9. Study Says - Blocking aP2 Protein Prevents Airway Diseases
10. Naloxone Prevents Heroin Overdose
11. A Drug That Prevents Blindness
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many of ... beholder, according to experts who offered insights and commentary in the current issue of ... full issue, click here . , For the American Society of Clinical Oncology ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg ... Legal Elite. The attorneys chosen by their peers for this recognition are considered among ... Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite Hall ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Australia,s successful biotechnology scientists, Dr Graham ... Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm is seeking ... ASX. Noxopharm is a clinic-ready company with its first ... study later this year. NOX66 ... cancer patients - the ability of cancers to become resistant to ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
Breaking Medicine Technology: